This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Arrowhead Pharmaceuticals, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: The Innovative Contributions of Phillip Lazzara
Introduction
Phillip Lazzara is a notable inventor based in Madison, WI (US). He has made significant contributions to the field of biotechnology, particularly in the development of RNA interference (RNAi) agents. His work focuses on innovative methods to inhibit the expression of the microtubule associated protein tau (MAPT), which is crucial in the study of neurodegenerative diseases.
Latest Patents
Lazzara holds a patent for "RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use." This patent describes RNAi agents and compositions that include these agents, along with methods for inhibiting the MAPT gene. The MAPT RNAi agents disclosed in the patent are designed to inhibit the expression of the MAPT gene effectively. These agents are conjugated to an antigen binding protein, which facilitates their delivery across the blood-brain barrier (BBB). The pharmaceutical compositions that include these MAPT RNAi agents can provide therapeutic benefits for various diseases, including Alzheimer's disease and other tauopathies.
Career Highlights
Phillip Lazzara is currently associated with Arrowhead Pharmaceuticals, Inc., where he continues to advance his research in RNAi technology. His innovative work has the potential to transform treatment options for patients suffering from neurodegenerative diseases. Lazzara's dedication to his field is evident in his focused research and development efforts.
Collaborations
Lazzara has collaborated with notable colleagues, including Zhao Xu and Jeffrey Carlson. These collaborations have further enhanced the research and development of RNAi agents and their applications in treating neurodegenerative conditions.
Conclusion
Phillip Lazzara's contributions to the field of biotechnology, particularly through his patent on MAPT RNAi agents, highlight his innovative spirit and commitment to improving therapeutic options for patients. His work at Arrowhead Pharmaceuticals, along with his collaborations, positions him as a key figure in the ongoing fight against neurodegenerative diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile